Duration of highly active antiretroviral therapy regimens

被引:71
作者
Chen, RY
Westfall, AO
Mugavero, MJ
Cloud, GA
Raper, JL
Chatham, AG
Acosta, EP
Taylor, KH
Carter, J
Saag, MS
机构
[1] Univ Alabama, HIV Outpatient Clin, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama, Div Infect Dis, Birmingham, AL 35294 USA
[3] Univ Alabama, Div Clin Pharmacol, Birmingham, AL 35294 USA
[4] Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA
关键词
D O I
10.1086/377271
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The median duration of highly active antiretroviral therapy (HAART) regimens was reported to be 11.8 months in one US study, but that study included both treatment-experienced and treatment-naive patients. The duration of initial HAART regimens for treatment-naive patients alone has not been reported. We selected 405 antiretroviral-naive patients who were seen at the University of Alabama at Birmingham HIV Outpatient Clinic from 1 January 1996 through 9 October 2001, and we assessed the duration of initial and successive HAART regimens in this group. Any antiretroviral medication change, excluding dosage changes, that lasted greater than or equal to14 days was considered to indicate the start of a new regimen. The median duration of regimens was determined by Kaplan-Meier analysis, and proportional hazards regression was used to identify factors associated with shorter duration of initial regimen. The median duration of initial regimens was 1.6 years, and medication toxicity-associated events were the cause of one-half of discontinuations. Only a history of opportunistic infection and injection drug use were significantly associated with shorter regimen duration.
引用
收藏
页码:714 / 722
页数:9
相关论文
共 29 条
  • [1] ABRAMOWICZ M, 2001, MED LETT, V43, P103
  • [2] Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
    Brodt, HR
    Kamps, BS
    Gute, P
    Knupp, B
    Staszewski, S
    Helm, EB
    [J]. AIDS, 1997, 11 (14) : 1731 - 1738
  • [3] VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    CAO, YZ
    QIN, LM
    ZHANG, LQ
    SAFRIT, J
    HO, DD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) : 201 - 208
  • [4] CHEN R, 2001, 8 C RETR OPP INF CHI, P145
  • [5] HIV-1 protease inhibitors - A review for clinicians
    Deeks, SG
    Smith, M
    Holodniy, M
    Kahn, JO
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02): : 145 - 153
  • [6] Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
    Detels, R
    Muñoz, A
    McFarlane, G
    Kingsley, LA
    Margolick, JB
    Giorgi, J
    Scharager, LD
    Phair, JP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (17): : 1497 - 1503
  • [7] Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
    Ferrer, E
    Consiglio, E
    Podzamczer, D
    Grau, I
    Ramon, JM
    Perez, JL
    Gudiol, F
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1999, 31 (05) : 495 - 499
  • [8] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
    Finzi, D
    Blankson, J
    Siliciano, JD
    Margolick, JB
    Chadwick, K
    Pierson, T
    Smith, K
    Lisziewicz, J
    Lori, F
    Flexner, C
    Quinn, TC
    Chaisson, RE
    Rosenberg, E
    Walker, B
    Gange, S
    Gallant, J
    Siliciano, RF
    [J]. NATURE MEDICINE, 1999, 5 (05) : 512 - 517
  • [9] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
    Finzi, D
    Hermankova, M
    Pierson, T
    Carruth, LM
    Buck, C
    Chaisson, RE
    Quinn, TC
    Chadwick, K
    Margolick, J
    Brookmeyer, R
    Gallant, J
    Markowitz, M
    Ho, DD
    Richman, DD
    Siliciano, RF
    [J]. SCIENCE, 1997, 278 (5341) : 1295 - 1300
  • [10] HIV-protease inhibitors
    Flexner, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) : 1281 - 1292